Pregabalin-to-Gabapentin Dose Equivalency
The most commonly used conversion ratio is approximately 1:6, meaning pregabalin 150 mg/day is roughly equivalent to gabapentin 900 mg/day, pregabalin 300 mg/day to gabapentin 1800 mg/day, and pregabalin 600 mg/day to gabapentin 3600 mg/day 1.
Evidence-Based Conversion Ratios
The 1:6 conversion ratio is supported by multiple lines of evidence:
Clinical trial data from a postherpetic neuralgia study demonstrated that pregabalin at one-sixth the dosage of gabapentin provided equivalent analgesic effects when substituted without changing dosing frequency 1
Pharmacokinetic modeling confirms that transitions using this ratio (gabapentin 900 mg/day to pregabalin 150 mg/day, gabapentin 1800 mg/day to pregabalin 300 mg/day, and gabapentin 3600 mg/day to pregabalin 600 mg/day) maintain therapeutic drug exposure 2
Perioperative pain studies found that pregabalin 300 mg/day had equivalent analgesic effects to gabapentin 1200 mg/day, supporting a 1:4 ratio in acute settings 3
Practical Conversion Approaches
Two validated transition methods exist 2:
Immediate Transition
- Discontinue gabapentin at the next scheduled dose
- Start pregabalin at 1/6th the total daily gabapentin dose
- Pregabalin-equivalent concentrations stabilize within 1 day
Gradual Transition (4-day overlap)
- Days 1-4: Give 50% of gabapentin dose + 50% of target pregabalin dose
- Day 5 onward: Discontinue gabapentin, continue full pregabalin dose
- Pregabalin-equivalent concentrations stabilize within 1 day of gabapentin cessation
Key Pharmacologic Differences
Pregabalin has distinct advantages that explain its greater potency 4:
- Bioavailability: Pregabalin maintains ≥90% bioavailability at all doses, while gabapentin drops from 60% at 900 mg/day to 33% at 3600 mg/day
- Absorption: Pregabalin has linear (first-order) absorption with peak levels at 1 hour; gabapentin has saturable (zero-order) absorption with peaks at 3-4 hours
- Dose-response: Pregabalin plasma concentrations increase proportionally with dose; gabapentin does not
Important Clinical Caveats
Cardiovascular Risk Considerations
Recent high-quality evidence reveals critical safety differences 5:
- Pregabalin carries a 48% increased risk of heart failure hospitalization/ED visits compared to gabapentin (AHR 1.48,95% CI 1.19-1.77)
- In patients with pre-existing cardiovascular disease, this risk increases to 85% (AHR 1.85,95% CI 1.38-2.47)
- Both medications increase long-term cardiovascular risks including DVT, PE, peripheral vascular disease, MI, and stroke 6
Clinical recommendation: In patients with cardiovascular disease or heart failure risk factors, strongly favor gabapentin over pregabalin despite the dosing convenience of pregabalin. The mortality and morbidity implications outweigh pharmacokinetic advantages.
Efficacy Differences
While the 1:6 ratio provides equivalent baseline effects 1, pregabalin demonstrates superior pain reduction in head-to-head trials:
- More rapid onset of analgesia 7
- Greater VAS score improvements at 12-14 weeks 8
- Better quality of life scores (SF-12/SF-36) 8
- Lower opioid consumption requirements 8
Renal Dosing
Both medications require dose adjustment for renal impairment 9. When converting in patients with CrCl <60 mL/min, apply renal adjustments to the pregabalin dose after calculating the 1:6 conversion.
Side Effect Profile
- Peripheral edema occurs significantly more with pregabalin 1
- Nausea/vomiting occurs more with gabapentin 8
- Somnolence and dizziness are comparable between drugs 1
- Gabapentin shows better effects on anxiety, insomnia, and fatigue 10
Titration After Conversion
If converting to pregabalin and pain control remains inadequate 1:
- Wait 2 weeks at the converted dose before increasing
- Titrate gradually by 150 mg/day increments every 3-7 days
- Monitor closely for peripheral edema and cardiovascular symptoms
- Maximum dose: 600 mg/day (higher doses increase adverse effects without proportional benefit) 7